BeiGene Q1 product revenue $410.3M (+57% YoY); BRUKINSA sales double to $211.4M

BeOne Medicines Ltd.

2023-Q1 EPS reported -$0.26 revenue$447,801,000

Net loss narrowed to $348.4M ($0.26 per share) from $435.2M a year ago; operating leverage improved.
Global BRUKINSA sales of $211.4M, up 103% YoY, driven by U.S. CLL/SLL launch ($138.8M U.S.).
Tislelizumab revenue in China $114.9M (+31% YoY); 10 approved indications in China.
Cash and short-term investments $3.8B as of March 31, 2023; operating cash outflow $563.8M in Q1.
R&D expenses $408.6M; SG&A $328.5M; gross margin improved to 80.1% from 75.1%.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeOne Medicines Ltd. reported the three months ended March 31, 2023 results: revenue $447.8 million, net income $348.4 million, EPS $0.26 per share.

Period: the three months ended March 31, 2023
Revenue: $447.8 million
Net income: $348.4 million
EPS: $0.26 per share
Result: reported results

Exact text from the filing

faster than operational expenses, BeiGene is well positioned for future growth.” First Quarter 2023 Financial Results Revenue for the three months ended March 31, 2023, was $447.8 million, compared to $306.6 million in the same period of 2022. • Product revenue totaled $410.3 million for the three months ended March 31, 2023, compared to $261.6 million in the same

View on SEC.gov

Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-23-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.